A Phase 1/2 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients With Glioblastoma or Non-Small Cell Lung Cancer
Black Diamond Therapeutics, Inc.
Summary
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer silevertinib (BDTX-1535) monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently ongoing.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Phase 2 Eligibility: Key Inclusion Criteria Required for locally advanced or metastatic NSCLC: * Measurable disease by RECIST 1.1 criteria. * Adequate bone marrow or organ function. * Life expectancy of ≥ 3 months. * Sufficient performance status. * Confirmed NSCLC, without small cell lung cancer transformation with or without brain metastases. * Disease progression following or intolerance of standard of care (excluding patients in the treatment-naïve non-classical driver cohort): * Cohort 1 (Non-Classical driver cohort): Advanced/metastatic NSCLC with a non-classical driver EGFR mutatio…
Interventions
- Drugsilevertinib monotherapy
Silevertinib (BDTX-1535) is a 4th generation irreversible brain penetrant EGFR MasterKey inhibitor, which targets a family of oncogenic EGFR classical and non-classical driver and resistance mutations in NSCLC.
Locations (19)
- University of AlabamaBirmingham, Alabama
- Banner MD Anderson Cancer CenterGilbert, Arizona
- City of Hope Orange County Lennar Foundation Cancer CenterIrvine, California
- Cedars Sinai Medical CenterLos Angeles, California
- Sibley Memorial Hospital Johns Hopkins MedicineWashington D.C., District of Columbia
- Mayo Clinic- JacksonvilleJacksonville, Florida